Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2016

Accounting Policies [Abstract]

Schedule of customers representing 10% or more of revenues

The following table sets forth customers or partners who represented 10% or more of our total revenues for 2016, 2015 and 2014:

	Years Ended December 31,
	2016		2015		2014
AmerisourceBergen Drug Corporation	22	%	25	%	34	%
McKesson Corporation	11	%	11	%	21	%
Cardinal Health, Inc.	<10	%	<10	%	15	%
Takeda Pharmaceuticals Company Limited	—	%	12	%	11	%

Schedule of customers representing greater than 10% of accounts receivable balances

Customers which represented greater than 10% of our accounts receivable balance as of December 31, 2016 and 2015 were as follows:

	December 31,
	2016		2015
McKesson Corporation	32	%	<10	%
AmerisourceBergen Drug Corporation	13	%	43	%

Schedule of property, plant and equipment estimated useful lives

Property, plant and equipment are recorded at cost and depreciated when placed into service using the straight-line method based on their estimated useful lives as follows:

	Useful Life
Buildings and improvements	15 - 40 Years
Computer equipment and software	5 Years
Furniture and fixtures	5 Years
Leasehold improvements	Lesser of Lease or Asset Life
Laboratory and production equipment	5 Years
Land improvements	10 Years

Property, plant and equipment, net consisted of the following as of December 31, 2016 and 2015 (in thousands):

	December 31,
	2016			2015
Land	$	700		$	700
Land improvements	300			300
Building and improvements	9,500			9,500
Computer equipment and software	13,866			13,193
Furniture and fixtures	2,401			1,725
Leasehold improvements	3,718			1,717
Laboratory and production equipment	6,449			5,683
Construction in progress	1,619			786
	38,553			33,604
Less: accumulated depreciation	(14,093		)	(4,879		)
Property, plant and equipment, net	$	24,460		$	28,725

Analysis of U.S. product sales allowances and accruals

Our U.S. product sales, which primarily represented revenues from Makena and Feraheme for 2016, 2015 and 2014 were offset by provisions for allowances and accruals as follows (in thousands):

	Years Ended December 31,
	2016		2015		2014
Gross U.S. product sales	$	748,839	$	561,255	$	190,512
Provision for U.S. product sales allowances and accruals:
Contractual adjustments	229,686		161,665		73,262
Governmental rebates	86,983		57,774		7,252
Total provision for U.S. product sales allowances and accruals	316,669		219,439		80,514
U.S. product sales, net	$	432,170	$	341,816	$	109,998

Schedule of components of basic and diluted net income (loss) per share

The components of basic and diluted net income (loss) per share for 2016, 2015 and 2014 were as follows (in thousands, except per share data):

	Years Ended December 31,
	2016			2015		2014
Net income (loss) - basic	$	(2,483	)	$	32,779	$	135,817
Dilutive effect of convertible 2.5% notes	—			—		1,654
Net income (loss) - diluted	$	(2,483	)	$	32,779	$	137,471
Weighted average common shares outstanding	34,346			31,471		22,416
Effect of dilutive securities:
Warrants	—			2,466		—
Stock options and RSUs	—			1,371		520
Convertible 2.5% notes	—			—		2,289
Shares used in calculating dilutive net income (loss) per share	34,346			35,308		25,225
Net income (loss) per share:
Basic	$	(0.07	)	$	1.04	$	6.06
Diluted	$	(0.07	)	$	0.93	$	5.45